Related Experiment Video
Updated: Jun 23, 2026
07:25
Assessing Murine Resistance Artery Function Using Pressure Myography
Published on: June 7, 2013
Dissecting complex traits: recent advances in hypertension genomics.
1Clinical Pharmacology Unit, Department of Medicine, Box 110, Addenbrooke's Hospital, Cambridge, CB2 2QQ, UK. kmo22@medschl.cam.ac.uk.
Genome Medicine
|May 15, 2009
Summary
Genome-wide association studies are identifying genetic risk factors for essential hypertension. A key finding is the SPAK kinase, a potential target for new blood pressure medications.
Area of Science:
- Genetics
- Cardiovascular Disease Research
- Pharmacogenomics
Background:
- Genome-wide association studies (GWAS) are increasingly identifying genetic risk alleles for complex diseases.
- Essential hypertension was initially resistant to GWAS findings but recent studies have yielded significant results.
- The identification of genetic factors is crucial for understanding disease mechanisms and developing targeted therapies.
Purpose of the Study:
- To review the progress of GWAS in identifying genetic risk factors for essential hypertension.
- To highlight the discovery of SPAK kinase as a novel antihypertensive drug target.
- To discuss the potential of GWAS in predicting drug response and side effects for personalized hypertension therapy.
Main Methods:
- Analysis of recent genome-wide association scans and meta-analyses for essential hypertension.
- Investigation of the role of SPAK (serine/threonine kinase) in regulating the sodium-chloride cotransporter (NCCT; SLC12A3) in the kidney.
- Review of ongoing GWAS efforts to identify alleles influencing antihypertensive drug response and adverse effects.
Main Results:
- Several genetic loci associated with essential hypertension have been identified.
- SPAK kinase has been identified as a novel target for antihypertensive drugs, regulating kidney NCCT function.
- Defects in this pathway are linked to Gordon's syndrome, a rare Mendelian hypertension disorder.
- GWAS are being employed to predict individual responses to antihypertensive medications.
Conclusions:
- Genome-wide association studies have successfully identified genetic factors contributing to essential hypertension.
- The discovery of SPAK kinase offers a promising new avenue for antihypertensive drug development.
- Future GWAS are expected to enable personalized drug therapy for hypertension, optimizing treatment efficacy and minimizing side effects.
Related Concept Videos
01:29Hypertension II: Pathophysiology
Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:30Hypertension III: Clinical Manifestations and Diagnostic Studies
Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
01:18Hypertension and Regulation of Blood Pressure
Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
01:11Genome-wide Association Studies-GWAS
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
01:28Hypertension I: Introduction
Hypertension is a widespread, long-term medical condition where blood pressure in the arteries remains elevated. It is characterized by systolic blood pressure readings of 130 mm Hg or above or diastolic blood pressure (DBP) readings of 80 mm Hg or higher. Unmanaged hypertension poses significant health risks, making the distinction between primary (or essential) hypertension and secondary hypertension crucial, as their management and implications vary.Primary HypertensionPrimary hypertension,...